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Abstract
Thomsen-Friedenreich (TF) antigen belongs to the mucin-type tumor-associated carbohydrate 
antigen. Notably, TF antigen is overexpressed in colorectal cancer (CRC) but is rarely expressed 
in normal colonic tissue. Increased TF antigen expression is associated with tumor invasion and 
metastasis. In this work, we sought to validate a novel nanobeacon for imaging TF-associated 
CRC in a preclinical animal model. We developed and characterized the nanobeacon for use with 
fluorescence colonoscopy. In vivo imaging was performed on an orthotopic rat model of 
colorectal cancer. Both white light and fluorescence colonoscopy methods were utilized to 
establish the ratio-imaging index for the probe. The nanobeacon exhibited specificity for TF-
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associated cancer. Fluorescence colonoscopy using the probe can detect lesions at the stage which 
is not readily confirmed by conventional visualization methods. Further, the probe can report the 
dynamic change of TF expression as tumor regresses during chemotherapy.
Data from this work suggests that fluorescence colonoscopy can improve early CRC detection. 
Supplemented by the established ratio-imaging index, the probe can be used not only for early 
detection, but also for reporting tumor response during chemotherapy. Furthermore, since the data 
obtained through in vivo imaging confirmed that the probe was not absorbed by the colonic 
mucosa, no registered toxicity is associated with this nanobeacon. Taken together, these data 
demonstrate the potential of this novel probe for imaging TF antigen as a biomarker for the early 
detection and prediction of the progression of CRC at the molecular level.
Despite recent advances in chemotherapeutics, colorectal cancer (CRC) remains a major 
cause of morbidity and mortality among cancers (1). Because CRC undergoes a protracted 
asymptomatic stage before it reaches the advanced stage, successfully detecting the early 
onset of the disease via routine screening will improve therapeutic outcomes and save lives. 
In that regard, colonoscopy is considered the gold standard for early detection. The process 
involves visual endoscopic inspection of the intestinal walls to detect polyps and adenomas. 
However, its effectiveness in the early detection of tumor growth is mitigated by its inability 
to disclose changes at the molecular level. For that reason, colonoscopy is ill suited for the 
assessment of tumors with a diameter of less than one centimeter (2). Recent studies have 
reported that the miss rate for this size-dependent technique may be as high as 20% for 
polyps (3). Additionally, those reports suggest that early detection of CRC is a far more 
difficult task than previously thought. Since in many cases, small or flat adenomas which are 
ten times more likely to become malignant than similarly sized polyps, are virtually 
indistinguishable from their surrounding tissue based on visual inspection alone (4). Further, 
colonoscopy lacks the capacity to detect cancer at the molecular level, thus leaving 
clinicians with no reliable metric capable of helping them determine whether a lesion is 
benign or malignant. These drawbacks have necessitated the development of novel 
technologies to achieve the early detection of CRC. One of the approaches is the integration 
of colonoscopy with an optical imaging modality. This innovation provides a robust method 
for early detection of CRC owing to its intrinsic coupling of detection with the underlying 
molecular-level pathology of the disease. Moreover, since molecular imaging methods can 
detect functional variations in tissue as opposed to changes in structure, they have the ability 
to focally highlight lesions with very high target-to-background ratios (5). Kelly et al. (6) 
demonstrated this notion using specific peptides that were identified through differential 
phase displays. In this work, the fluorescence (FL)-labeled peptide could detect CRC even 
when the cancer was limited to the submucosal layer using FL colonoscopy. In a similar 
approach, Hsiung et al (7) reported the use of phage display to develop a specific peptide 
capable of recognizing dysplastic colonocytes. After labeling the peptides with Fluorescein, 
the topically applied reporter can detect dysplastic colonoctyes with 81% sensitivity and 
82% specificity using confocal microendoscopy.
In a different approach, we integrate nanotechnology with molecular imaging to develop a 
multiplex nanobeacon with which to image CRC using FL microendoscopy. The 
nanobeacon was coated with peanut agglutinin (PNA) on the surface as the recognition 
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molecules to recognize Thomsen-Friedenreich (TF) antigen (Galβ1, 3GalNacα-O-Ser/Thr) 
expressed in CRC. Different from other colon cancer imaging targets that require targeting 
agents to remain intact through systemic delivery, TF expression is found on the surface of 
epithelial cells; thus localized, topical delivery can be implemented to improve the 
efficiency of the targeting agents. Further, TF’s substantially large size and accessibility at 
the cell surface coupled with the occurrence of tandem repeated regions (most TF 
disaccharides are expressed on the tandem repeated MUC protein backbone) help amplify 
the targeting signal. Based on these results, it seems reasonably certain that high expression 
of TF antigen in CRC combined with its absence from normal tissue represents a unique 
association in colorectal carcinoma that exhibits the qualities of a prognostic biomarker.
In this study, we report the validation of the specificity of the nanobeacon developed in our 
laboratory (Fig. 1). In addition to the presence of PNA on the surface, the nanobeacon is 
comprised of a polystyrene core encapsulated coumarin 6 dyes within its central core. The 
surface was coated with a thin layer of two polymers, poly(methacrylic acid) (PMAA) and 
poly(N-vinyl acetamide) (PNVA). Here, the former is used to attach the PNA through 
covalent bonding while the latter helps reduce nonspecific interaction with the mucous layer 
of the gastrointestinal tract (8, 9). In the recent past, we demonstrated the specificity of the 
nanobeacon in vitro using human CRC cells and biopsy specimens (10). The data obtained 
from that work showed that the nanobeacon can report the dynamic expression of TF 
antigen in CRC cells and tissues. In the current work, we demonstrated for the first time the 
in vivo imaging of TF-associated CRC using the nanobeacon along with an in-house 
developed FL microendoscope. Employing this imaging system, our in vivo imaging data 
not only confirms our previous reports of the nanobeacon’s specificity for TF antigen (10–
12), but additionally expands our findings by demonstrating that the nanobeacon can detect 
CRC weeks before the tumor can be visualized by white light (WL) colonoscopy. 
Furthermore, by using a standardized regional FL ratio imaging approach, we generated a 
ratio-imaging index (RII) for the nanobeacon. Using this approach, we demonstrated that the 
nanobeacon can be used in conjunction with colonoscopic imaging to provide early 
detection and assess tumor response to chemotherapy.
MATERIALS AND METHODS
Reagents
Cell culture mediums were obtained commercially at high grade, while the anti-human TF 
monoclonal antibody was obtained from Lifespan Biosciences. Immunohistochemical 
staining for colorectal section samples was performed using the avidin-biotin peroxidase 
complex method available in a commercial kit (Vector laboratories).
Nanobeacon synthesis and characterization
The synthesis of the nanobeacon was described in our recent publication (10) but 
accomplished here with major modifications aiming for in vivo and clinical applications 
(Supplementary data).
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To estimate the encapsulation properties of coumarin 6, FL nanospheres with only surface 
PNVA chains were prepared at a different concentration of the dye during the 
copolymerization. Vinylbenzyl group-terminated PNVA (1.0 g) and styrene (1.0 g) were 
dissolved in 15 mL of the ethanol/water mixture containing AIBME (approximately 1 mol% 
of the total monomers) and coumarin 6 (0.1 – 1% of the total monomers). The nanospheres 
were prepared in the same manner as that described in the previous paragraph. PNA 
molecules were covalently conjugated on the surface of the nanobeacon through the 
coupling of the amino groups of PNA with the carboxyl groups of PMAA using 1-ethyl-3-
(3–dimethylaminopropyl) carbodiimide as a catalyst. The resulting PNA-immobilized 
fluorescent nanospheres with surface PNVA chains were purified by changing the dispersion 
media several times. Finally, purified water was used in the filtration process to provide the 
nanobeacon solution at a concentration of 20 mg/mL.
The homogeneity and particle size were assessed via scanning electron microscopy (SEM) 
and dynamic light scattering (DLS). While the composition, quantity and thickness of the 
surface coating polymer were assessed using X-ray photoelectron spectroscopy (XPS). The 
amount of PNA was quantified by its hydrolysis from a known concentration of nanobeacon 
in the solution using hydrochloric acid. Under such conditions, PNA was also hydrolyzed 
into amino acids which were separated from the nanoparticles by active filtration. In 
addition, the weight amount of PNA relative to the concentration of the nanobeacon was 
quantified using adsorption isotherm approach where we examined several conditions of 
PNA immobilization with 10 mg of the nanobeacon. Afterward, the amount of the PNA 
immobilized on the nanobeacon was quantified by ninhydrin assay and compared to a 
calibrated PNA concentration curve. While the amount of coumarin 6 present in the 
nanobeacon was assessed using UV-Vis spectroscopy. Further, we used gel permeation 
chromatography (GPC) to quantify the distribution ratio of the polymers.
Cell line and animal models
Human HCT116 cells were maintained in Leibovitz’s L15 with 1.5 mM McCoy’s 5A. The 
medium was supplemented with fetal bovine serum (10%, v/v) and penicillin-streptomycin 
(100 U/mL).
Eight to ten-week-old female nude rats (rnu/rnu) were purchased from Harlan Laboratories. 
While wild type C57BL/6 mice were acquired from Jackson Laboratory. All experimental 
protocols were approved by the Vanderbilt University Institutional Animal Care and Use 
Committee.
To generate an orthotopic model of CRC, the lower abdominal region of isoflurane 
anesthetized female nude rats rnu/rnu (200 – 250 g) were sanitized with iodine prior to 
longitudinally incision (approximately 2 – 2.5 cm) with a surgical scalpel. The cecum was 
pulled out slightly and placed on a sterilized gauge to reveal the descending colon. 
Approximately, half a million HCT 116 cancer cells (10 µL) were injected into the 
submucosa of the descending colon. After injection, the descending colon and the cecum 
were returned to their normal positions and the wound closure was achieved in a double 
layer fashion using silk-based sutures. Tumor growth was monitored by FL and WL 
colonoscopy weekly until the tumors were detected at the earliest detectable time point.
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White light colonoscopy
Visual examination of the colon before and after tumor implantation, and then at regular 
weekly intervals using an Olympus ENF-P4 endoscopic system (Olympus Optical Co.) 
equipped with a digital USB video camera (Image Pro Medit Inc.) and a 150 W halogen 
light source. The process began by inflating the colon of prone, isoflurane anesthetized mice 
using a modest stream (1.74 psi) of air (Air-1000, TopFin). The endoscope (diameter 3.4 
mm) was inserted forward to the splenic flexure and was withdrawn slowly while capturing 
the video. The colonic epithelial tissues were examined via a monitor, and the data was 
captured as video and photos.
Fluorescence colonoscopy
Immediately following WL colonoscopy, the animals were subjected to FL colonoscopy. 
The nanobeacon was topically applied to the mucosa using a 360-degree spray catheter 
(Hobbs Medical Inc.). Thirty minutes following nanobeacon application, the probe was 
removed completely by suctioning using a syringe. Excess materials were completely 
removed by additional spraying of the colon with washing solution, such as PBS. FL 
colonoscopy was performed using a high-resolution and custom-built epi-fluoresecence 
microendscope to acquire in vivo imaging data. The system is comprised of a compact CCD 
camera (Point Grey Research), a high-power light emitting diodes (Luxeon) and micro fiber-
optic bundles (Fujikura). The spatial resolution of the microendoscope was achieved using a 
gradient index lens assembled to the distal tip of the fiber bundle. The configuration of the 
optics is aligned so that the tip of the fiber bundle is imaged onto the tissue surface with 
demagnification, thereby increasing the spatial sampling frequency imposed by the light-
guiding cores of the fiber bundle. The degree of demagnification corresponds to the increase 
in spatial resolution. All data were collected using coumarin 6- or RFP-compatible 
excitation/emission dichroic filters, and a fiber optics with a diameter of 600 µm which 
provides an overall optical resolution of 0.4 µm (13).
The procedure commenced with the smooth insertion of the endoscope into the anus of the 
anesthetized rats/mice. The endoscope could survey the large intestine all the way to the 
splenic flexure. Recording of the imaging data began as the endoscope was slowly 
withdrawn.
Standardized Regional Fluorescence Ratio imaging
The large intestine was virtually segmented into two regions in which the splenic flexure of 
the animal was considered a control tissue; as this region provides an anatomically fixed 
reference that could be reliably located between imaging sessions. Measurements of the FL 
signal at the splenic flexure were taken before and after application of the nanobeacon in the 
descending colon. The pretreatment and posttreatment signals were then averaged and used 
as F0 – an index of non-specific FL signal. The tumor-bearing region of the colon was 
defined as a region of interest (ROI) and measurements of the FL signal emanating from this 
area were averaged and defined as FROI – an index of tumor specific FL. The FROI/F0 ratio 
was then established by averaging the data values determined from 6 tumor-bearing animals.
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Quantitative analysis
Quantitative analysis of FL colonoscopy luminance was conducted using the MATLAB 
software package (MathWorks, Inc., USA). Data from each colonoscopy image was initially 
combined to automatically create a global threshold level using Otsu’s method (14). This 
threshold was applied to each image to create binary images representing dark and bright 
pixels. Percentages of overall bright pixels in each image are presented. While RGB images 
of TF histology were analyzed and segmented into pixels where intensities of the brown 
color were analyzed and presented as percentages of overall brown dominated pixels in each 
slide.
Immunohistochemistry
The freshly isolated descending colons of the rats were removed, fixed in 4% 
paraformaldehyde, embedded in OCT and frozen, after which section slides were prepared. 
Slide sections were stained with TF monoclonal antibodies using the avidin-biotin 
peroxidase complex method available in a commercial kit (Vectastain ABC Elite Kit, Vector 
Laboratories, USA) and analyzed by WL microscopy.
Statistical analysis
Data were analyzed using GraphPad software (GraphPad Prism version 4.0 for Mac). 
Results are presented as mean ± SE. Differences were analyzed with student’s t-test for two-
factor ANOVA, and the results are considered significant at a P value of <0.05.
RESULTS
Specificity and quantitative analysis of the components makeup of the nanobeacon
Homogeneity, particle size and the FL property of the nanobeacon were assessed using SEM 
and FL microscopy. As shown in Fig. 2 A and B, the nanobeacon is homogenous in size and 
shape. The FL signal emitted from the nanobeacon is uniform, which suggests equal 
distribution of coumarin 6 dye within the particle’s central core. The specificity of the 
nanobeacon was confirmed by incubation with HCT-116 cells (Fig. 2 C). Of note, restriction 
of the FL signal to the cell rim corroborates with the notion that TF expression is 
predominately located in the extracellular membrane. This interpretation of the data is also 
supported by information obtained by high-resolution confocal microscopy, which again 
demonstrates that the nanobeacon, and thus TF expression, are restricted to the extracellular 
membrane (Supplementary Fig. S1). To assess the level of non-specific binding between the 
nanobeacon and endogenous cell-surface antigens, the nanobeacon was incubated in a TF-
deficient batch of cells. In this experiment, TF expression was depleted from the cell surface 
via treatment with glycanase using the procedures described by Singh et al. (15). Using this 
method, the TF antigen removal on the cell surface was quantified by cell sorting analysis. 
We confirmed that more than 50% of the antigen was depleted upon an overnight exposure 
to the enzyme (Supplementary Fig. S2). Following TF depletion, the cells were again 
incubated with the nanobeacon and analyzed for FL signal. As shown in Fig. 2 D, removal 
of TF from the surface of CRC cells resulted in a profound attenuation of FL signal. This 
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data supports the conclusion that binding of the nanobeacon to the cell surface is TF-
dependent.
To further characterize the nanobeacon’s physical property, the composition, quantity and 
thickness of the surface coating polymer were assessed using XPS. As shown in Table 1, 
polystyrene accounts for the majority of the nanobeacon, and its surface is coated with 
PNVA and PMAA at a thickness of approximately 15 nm. To facilitate the quantification of 
PNA associated with each nanoparticle, PNA was quantified in its hydrolyzed form. We 
found that 200–300 PNA molecules had been covalently linked on each nanobeacon 
particle. Furthermore, using an adsorption isotherm technique, we learned that quantitatively 
there are about 2 µg of PNA for every 1 mg/mL of the nanobeacon (supplementary Fig. S3). 
In addition, we found that coumarin 6 dye constitutes approximately 0.05% of the 
nanobeacon’s overall weight. Overall, the nanobeacon ranges from 300,000–1,500,000 
daltons, which is equivalent to 350 nm. Most importantly, we can control the size of the 
nanobeacon by varying polymer ratios during the synthesis. However, it is crucial to 
maintain the size above 300 nm to prevent the nanobeacon from being absorbed by the 
intestinal mucosa and subsequently becoming toxic to the peripheral organs due to systemic 
distribution (10).
Topically applied nanobeacon is nonabsorbable by colonic epithelial tissue
As mentioned earlier, we performed the biodistribuiton of the nanobeacon using an 
orthotopic mouse model in the past (10). In that work we found out that the nanobeacon was 
not absorbed by the colonic mucosa. In this work, we want to further confirm that notion by 
imaging using FL colonoscopy. Three groups of wild-type mice (n=6, each) were treated 
with (i) saline; (ii) coumarin 6 dye or (iii) nanobeacon. As shown in Fig. 3 A, the FL signal 
emitted by the nanobeacon-treated animals was comparable with that of mice treated with 
saline. This result supports the conclusion that the nanobeacon exhibits negligible non-
specific interaction with endogenous antigens and that retention after washing is dependent 
on TF expression. In contrast, the coumarin 6 dye readily diffused through the mucosa and 
produced an enhanced FL signal which depicted the colonic crypts of the descending colon.
Ratio-imaging index
In this task, we developed a ratio imaging method which enabled us to create an imaging 
index specific to the nanobeacon. This standardized metric is useful for enhancing the 
probe’s precision and reproducibility relative to its cancer prediction capability. To generate 
a RII for each value of F0 and FROI, we averaged the data obtained from 6 orthotopic CRC 
rats. For a nanobeacon concentration of 2 mg/mL, the RII of the nanobeacon FROI/F0 was 
determined to be 1.3 (Table 2). Using this index, we hypothesized that an RII value derived 
from any screening subject larger or equal to 1.3 could be characterized as cancer suspect. 
Subsequent in vivo imaging using this parameter demonstrated that an RII of 1.3 represents 
the threshold for early CRC detection. The results of this analysis suggest that the 
nanobeacon binds to CRC tissue with greater avidity compared to a noncancerous area. The 
mean signal intensity in the tumor region was significantly higher compared to the untreated 
control splenic flexure.
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The nanobeacon leverages colonoscopy for early CRC detection
Using the established RII, we were able to distinguish TF-associated CRC from normal 
colonic tissue in vivo. The advantage of this approach is that it is both practical and 
clinically relevant because we can utilize the FL signal emitted by the nanobeacon for direct 
diagnosis without the need to perform imaging on control subjects. As shown in Fig. 3 B, 
four weeks after tumor induction, FL colonoscopy assisted by the nanobeacon (2 mg/mL) 
detected the tumor with an RII index above 1.3 (p<0.001). Quantitatively, the FL signal of 
this early stage CRC was 52-fold higher than that of the control tissue (p<0.05) (Fig. 3 C), 
an observation confirmed by IHC data. The intensity of TF-stained CRC specimens was 35-
fold higher than the control (p<0.05). Altogether, it became apparent that at the early stage 
of tumor development, WL colonoscopy was not sufficient to enable a decision despite or 
observation of an irregular surface pattern on the gastric mucosa. However, FL colonoscopy 
data detected the TF expression and reported CRC with certainty.
Six weeks after injecting the cells into another group of animals, the resultant tumors were 
large enough to be detected by WL colonoscopy. As the tumors grew, TF expression 
became more prominent (16). Therefore, the FL signal that resulted from binding the 
nanobeacon to the TF-associated tumor increased markedly. Quantitative analysis of TF 
expression from FL colonoscopy imaging corroborates with IHC data. This suggests that TF 
expression is statistically significant in CRC compared to normal tissue and that the RII is 
approximately 1.5 (p<0.05) (Fig. 3 C). At this stage, the FL signal of the tumor was more 
than 60-fold higher compared to the control (p< 0.05). Likewise, the level of TF expression 
has a significant relation to the reported FL signal obtained from colonoscopy and was more 
than 60-fold different from the dissected tumor compared to the control tissue (p<0.05).
The nanobeacon can be used to distinguish tumor grade and report tumor response to 
chemotherapy
Having demonstrated that the nanobeacon can detect tumors with specificity, next we 
investigated whether nanobeacon-mediated detection of TF antigen correlated with tumor 
size. We designed two cohorts of animals (n = 9, each). One of these cohorts was the 
orthotopic model of CRC where nude rats were induced with HCT-116 CRC cells to 
generate TF-specific tumor in the descending colon. The second cohort was comprised of 
control animals in which no tumor model was invoked. FL colonoscopy was performed on 
both groups of animals and RII values were obtained. We graded the tumor using the criteria 
such that a grade 0 tumor indicated that WL colonoscopy could detect structural anomalies 
of the epithelial lining. However, at this stage WL imaging alone could not reliably detect 
the presence of the tumor. A grade 1 tumor was defined such that it might be comparable to 
a small but the adenocarcinoma was reliably detectable by WL colonoscopy. While a grade 
2 tumor was defined as those in which the tumor size reached approximately 1/8 of the 
diameter of the colon. As shown in Fig. 4 A, the RII values increased significantly at the 
threshold between the control and early CRC tissue. However, the FL signal began to level 
off as tumor size increased. This characteristic implies that the probe is suitable for early 
diagnosis applications. When we compared tumor size to the control for each group of tumor 
grades, the enhanced FL signal intensity was clear and statistically different from the control 
(P<0.01).
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Having established the detection threshold, we then focused on validating if the nanobeacon 
could detect the dynamic change of TF expression during chemotherapy. Selected animals 
that had grade 2 tumors were treated with paclitaxel during a one-month therapy regiment 
that included 4 paclitaxel treatments (10 mg/kg via tail vein injection) (Fig. 4 B). 
Colonoscopies were performed immediately following and 30 days after the first treatment. 
At the beginning of the therapy, the tumor was apparent, and FL colonoscopy detected 
dense, abnormal and asymmetric crypts in the descending colon. The FL signal was above 
the 1.3 detection threshold. Biopsy samples stained with antibodies to the TF antigen also 
reported similar observation as seen in the FL colonoscopy, such that an increase was noted 
in the number of asymmetric crypts in which the TF antigen was overexpressed. At the end 
of the therapy period, the tumor was not detected by either WL or FL colonoscopy. The 
animals were sacrificed, the descending colon dissected and tumor regression confirmed by 
visual examination (data not shown). Histology confirmed that the colon was free of tumors. 
Taken together, this data suggests that the nanobeacon exhibits the potential for imaging 
tumor response during chemotherapy.
DISCUSSION
For imaging surface CRC biomarkers, the TF antigen continues to receive a remarkable 
amount of attention. Not only is the antigen overexpressed exclusively in CRC, but it is also 
carried by MUC1 on the apical surface of the colonic mucosa (17). Therefore, the antigen 
represents a unique target for topically applied molecular imaging probes. Although topical 
probes have been developed in the past for use in CRC imaging (7), we believe this is the 
first time a topical FL nanoparticle probe has been designed specifically for that purpose. 
Notably, the probe was alienated from the blood circulation, thus, reducing the potential of 
toxicity. In the recent past, we demonstrated that the nanobeacon was not incorporated into 
the systemic distribution process upon topical application using an orthotopic mouse model 
(10). That data verified that there was no detectable FL signal in the serum or other organs 
of an orthotopic mouse model several hours after applying the nanobeacon to the colon. In 
the current study, we hypothesize that FL colonoscopy can also be used to assess the 
distribution of the topical nanobeacon. As the TF antigen is absent from normal colonic 
tissue, applying the nanobeacon to the colon of control animals would not yield FL signals. 
Further, if the nanobeacon is not absorbed by the mucosa, then no FL signals should exist. 
As shown in Fig. 3 A, treatment of the nanobeacon on the normal colon emits a background 
FL signal as low as that of the saline-treated counterparts. Our observation corresponds with 
a report by Jani et al., who used I125-labeled polystyrene nanoparticles to study absorption 
across the gastrointestinal tract. Their work showed that following the topical application of 
300 nm-polystyrene microspherers to the rat intestines, they were not absorbed by the 
colonic mucosa and thus were completely absent in the blood (18).
Next, we wanted to determine whether the nanobeacon is capable of detecting TF-associated 
CRC at the early stage. To that end, we developed a novel orthotopic CRC rat model to 
assess the specificity of the nanobeacon. While orthotopic CRC tumors have been reported 
in the literature (6, 19, 20), no such models have yet been developed on rats. In this model, 
we implanted human CRC cells in the colonic submucosa using an open surgical method. 
Different from the subcutaneous model, rats were injected with fast-growing and highly 
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aggressive cancer cells, such as HCT-116; however, that did not guarantee robust tumor 
growth. Injection of the same amount of cells (5.0 ×105) in subcutaneous and submucosal 
models resulted in a very different tumor growth kinetic (Supplementary Fig. S4). Tumors in 
the subcutaneous model grew faster, which resulted in a mass effect within days rather than 
weeks. In the orthotopic model, the apparent HCT-116 CRC was detected by visual 
inspection after ten weeks of tumor induction. Tumors implanted orthotopically in rats are 
very similar to those that affect humans, since once formed in the colon, the tumors invade 
the colonic submucosa and latter progress to the serosa. The earliest time at which we can 
detect the early onset of the disease is approximately four weeks post cell injection using 
WL colonoscopy. While the small lesion was not obvious and did not prove sufficiently 
informative to help render a categorical decision regarding the presence of CRC, the 
nanobeacon demonstrated the ability to detect such molecular transformation. In fact, when 
we sprayed the colon with the nanobeacon, we noted a remarkably high FL signal at the 
suspected area. As shown in Fig. 3 B, these data suggest that the nanobeacon was retained in 
the lesion area and emitted a FL signal with an approximate FROI/F0 index greater than 1.3. 
To correlate the imaging with biological events, the animals were sacrificed, after which the 
descending colons were collected for immunohistochemistry analysis. The results showed 
intense TF antigen staining in the colonic tissue of the lesions, particularly in the crypts, and 
that the antigen was certainly the driving force behind the PNA-derivatized nanobeacon 
binding.
During the course of work, we noted that the FROI/F0 index increases as the tumor size 
increases. As demonstrated in Fig. 4 A, a large tumor has a FROI/F0 index of 1.5 versus the 
1.3 of an early-stage tumor. Since our strategy for using the nanobeacon is to leverage early 
detection, we are not interested in large tumors which can certainly be detected readily by 
WL colonoscopy. The relationship between tumor size and RII values suggests that there is 
a substantial difference in the index value between the control and early-stage tumors 
(P<0.01), and that difference maintains substantial between an early-stage tumor and a CRC 
grade 1 tumor. However, the gap narrowed between established tumors. Taken together, the 
data presented in the work suggested that the nanobeacon can be used not only for the early 
detection of CRC, but is also useful for reporting the response of cancer during 
chemotherapy.
In conclusion, we demonstrated the integration of nanotechnology with cancer imaging, an 
approach that offers several advantages that cannot be achieved by other methods. The 
nanobeacon can be used for the enhanced early detection and characterization of CRC, and it 
is suitable for screening colonoscopy. Further, preoperative endoscopic imaging can be 
helpful in localizing flat, small or subtle colonic lesions that may be difficult to identify by 
inspection during surgery. There remain a few important caveats; currently, little is known 
about the level of TF expression between endogenous flat adenocarcinoma and small tumor 
generated by injection of human carcinoma cells in the submucosa. Because the endogenous 
flat adenocarcinoma can proceed without major changes in cell surface glycosylation and 
this may undermine the application of the nanobeacon for early detection of CRC. To 
address this problem, we are attempting to test the nanobeacon on freshly dissected flat 
polyps. In addition, issues such as tissue autofluorescence due to the use of visible light need 
to be addressed in order to facilitate the technology for human use. Nevertherless, we 
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believe the development of a topically applied FL agent combined with extant imaging 
technologies make this project ideal for clinical translation.
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Novelty and Impact Statements
Thomsen-Friedenreich (TF) antigen is commonly present in cancer cells and in the 
colorectal mucous of patients with colorectal cancer. Biopsy samples taken from 
colorectal cancer patients showed that the TF antigen is overexpressed by hyperplastic 
and neoplastic colorectal cancers but not expressed in normal mucosa. In this work, we 
describe the development of a fluorescence nanoparticle for imaging TF antigen using 
fluorescence colonoscopy. The specificity of the probe was demonstrated in its ability to 
detect TF-associated colorectal cancer in the early stage, and the dynamic change of TF-
based CRC during therapy. Based on these results, we hypothesize that the nanobeacon 
exhibits the qualities of a prognostic agent for detection colorectal cancer.
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Figure 1. 
Design and physical properties of the nanobeacon for FL colonoscopy. The nanobeacon is 
comprised largely of polystyrene polymer and its surface was coated with a thin layer of 
PNVA and PMAA polymers. The PNVA is employed to reduce nonspecific binding to 
normal colonic mucosa, while PMAA provides a handle for bioconjugation via carboxylic 
groups. Approximately 200–300 PNA moieties are attached to the nanobeacon through 
covalent bonding to the PMAA polymer as recognition molecules for TF antigen. The 
optical feature of the nanobeacon is provided by coumarin 6 dyes encapsulated within the 
core of the nanoparticle. Quantitatively, coumarin 6 dye constitutes approximately 0.05% of 
the overall weight of the nanobeacon.
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Figure 2. 
Demonstration of the size, shape, optical characteristics and specificity of the nanobeacon. 
Homogeneity of the size, shape and fluorescence of the nanobeacon were confirmed by 
SEM (A) and FL microscopy (B), respectively. The specificity of the nanobeacon for TF 
antigen expressed on the surface of human CRC cells was tested on HCT-116 cells. Cells on 
chamber slides were treated with the nanobeacon (2 mg/mL) for 20 minutes in the incubator 
(25° C, 2% CO2). Following incubation, the cells were washed twice with DPBS and 
observed via FL microscopy (C). The dynamically specific response of the nanobeacon was 
demonstrated in HCT-116 cells. In this work, the TF antigen resident on the surface of the 
cells was removed by glycanase before treating the cells with the nanobeacon (2 mg/mL). 
As a consequence of TF removal, the FL signal was weakened significantly (D). Exposure 
time in FL observation was 400 ms at a magnification of X 200 each.
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Figure 3. 
(A) In vivo assessment of the biodistribution of the topically applied nanobeacon in wild-
type mice. FL colonoscopy was performed after the colons of 3 cohorts of mice (n = 6, each) 
were treated for 30 minutes with saline, coumarin 6 dye or the nanobeacon delivered by a 
360° spray catheter. (B) Representative images of WL versus FL colonoscopy for the early 
detection of CRC. Untreated control and HCT-116-induced rats, including those with early 
(4 weeks post-tumor cell injection, second column) and late (6 weeks post-tumor induction, 
third column) stage tumors (n = 6, each group) were screened by WL colonoscopy. The 
early-stage tumor (second column) was flat (grade 0), which impeded detection by WL 
visualization. In contrast, the result of ratio imaging using FL colonoscopy suggested that 
tissue anomaly could be CRC since the FROI/F0 index > 1.3 (p<0.001, n = 18, three 
measurements per rat). After FL colonoscopy, tissue in the descending colon was collected 
for histology, and the data corroborates with that obtained from FL colonoscopy. In larger 
tumors (grade 2)(third column), both WL and FL colonoscopy can detect the lesion with a 
substantial level of confidence. As the tumor grew larger, TF expression became 
demonstrably higher than in smaller tumor. As a result, the ratio imaging FROI/F0 index was 
>.5 (P<0.05, n = 18, three measurements per rat). (C) Quantification of the signal intensity 
emitted from the nanobeacon and histology data as a function of tumor size using Matlab 
analysis. Both techniques showed significantly increased signals in flat tumor (grade 0) 
compared to control. In additon, larger tumors exhibited stronger signals compared to 
smaller tumors. Data are presented as mean ± SE *, P<0.05; **, P<0.001.
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Figure 4. 
(A) Correlation between the ratio imaging index FROI/F0 with tumor size. Each data point 
represents the FROI/F0 ratio of a single HCT-116-induced rat. The tumors were allowed to 
grow and their sizes were assessed using WL colonoscopy starting from grade 0 to grade 2. 
At each classified stage of tumor progression, statistically significant differences in FROI/F0 
were recorded (P<0.01). This result supports the conclusion that TF antigen expression 
increases with tumor progression and confirms the reliability of the nanobeacon to report 
this increase; (B) Nanobeacon and FL colonoscopy were able to report the dynamic change 
of TF antigen as the tumor regressed during chemotherapy. Grade 2 CRC-tumor bearing rats 
(n = 3) were treated with a high dosage regimen of paclitaxel (10 mg/Kg) over a period of 
approximately one month per the detailed treatment timeline. Prior to chemotherapy, 
stereotactically guided WL and FL colonoscopies were performed to determine the location 
of the suspected tumor. A tissue biopsy was performed at the location defined using a 
retractable needle to confirm CRC pathology. Upon completion of the treatment, WL and 
FL colonoscopies were performed prior to tissue collection for visual examination and 
histology.
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Table 1
Overall physical property of the nanobeacon.
Physical properties Actual Values Techniques
Mw PMA:PNVA 12000±1000 : 8000±2000 GPC
Thickness of PMA/PNVA 15 nm XPS, 1HNMR
Ratio Styrene:PMA:PNVA 600 : 3 : 2 NMR
Mw Nanobeacon 300,000–1,500,000 GPC
Surface Fabricated PNA 2–4 µg/mg nanoparticle
200 – 300 PNA molecules
Adsorption Isotherm
Ninhydrin assay
Nanobeacon diameter 300 – 350 nm SEM, DLS
FL intensitya 300,000b Fluorometer
Coumarin 6 per nanoparticle 0.05 wt% UV-Vis
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Table 2
Ratio-imaging index FROI/F0 of the nanobeacon tested on an orthotopic rat model of CRC (n = 6) at a 
concentration of 2 mg/mL.
Ratio Imaging Fluorescence
Mean
Fluorescence
P values FROI/F0
Splenic flexure 131.7 ± 0.08 < 0.001 1.3
Tumor 170.1 ± 0.2 < 0.005
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